Alumis (ALMS) tumbles on Phase 2b LUMUS endpoint miss
Alumis Inc. shares plunged about 57% after Phase 2b LUMUS missed overall primary and key secondary endpoints, though the high–interferon subgroup met them. HC Wainwright upgraded and cut its target to $15; Wells Fargo cut to $25.
Alumis Inc. (NASDAQ:ALMS) plunged about 57% after Phase 2b LUMUS missed its overall primary and key secondary endpoints, though the high-interferon subgroup met them. Brokers cut price targets, with Wells Fargo lowering its target to $25 and HC Wainwright to $15, even as HC Wainwright upgraded the stock.